Quick Dispatch:
Your glutathione and lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your glutathione and lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports ships.
Need Help?
Questions about glutathione and lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for glutathione and lung cancer NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis | EMBO Reports in your area.
Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer
24.96
Illustration of glutathione-responsive paclitaxel dimeric nanoparticles...
26.64
Glutathione Depletion and Stalwart Anticancer Activity of Metallotherapeutics Inducing Programmed Cell Death: Opening a New Window for Cancer Therapy
22.68
A study from the Birsoy lab showed that the antioxidant glutathione, when operating inside mitochondria, is a key factor enabling tumors to spread from the breast to the lung. #RockefellerScience #YearInReview
21.62
Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression: Cancer Cell
21.48
Glutathione-Dependent Pathways in Cancer Cells
26.00
Frontiers
22.69
